Alcon has received approval from the FDA for its AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL. The new IOL is designed to address presbyopia and pre-existing corneal astigmatism at the time of cataract surgery in adult patients who desire good near, intermediate and distance vision with an increased potential for spectacle independence. The product is already commercially available in the European Union, Australia, Canada, and many countries in Central and South America and Asia.
"The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visual needs of patients," Sergio Duplan, Alcon Region President for North America, said in a company news release. "We are committed to delivering ongoing innovation that enables surgeons to provide the best possible outcome for their patients."
"Correcting presbyopia and astigmatism, with one lens, at the time of cataract surgery is a great benefit to patients and can improve patient satisfaction," said Dr. Stephen Lane, Medical Director, Associated Eye Care and Adjunct Clinical Professor at the University of Minnesota. "The introduction of this advanced technology IOL gives us an additional treatment option to help reduce dependence on spectacles for patients with astigmatism."
Alcon plans to commercialize AcrySof IQ ReSTOR +3.0D Multifocal Toric IOLs in the United States on a rolling basis starting in the first quarter of 2017.